ProQR Therapeutics NV (PRQR) Stock Analysis

AI analysis of ProQR Therapeutics NV (PRQR)

Hold

ProQR Therapeutics is currently trading at $1.32, significantly below its 52-week high of $2.65, indicating potential upside. However, the stock has a low RSI of 39.15, suggesting it is nearing oversold territory, but it also reflects weak momentum. The company has a gross margin of 100%, which is excellent, but it has reported consistent net losses, with a net income loss of €13,383,000 in Q1 2026. The main risk is the company's ongoing financial losses and reliance on external financing, as evidenced by a recent direct offering that caused a 20% drop in share price. Given these factors, it may be prudent to hold rather than buy at this time, as the stock may need to stabilize before a clear buying opportunity arises.

Analyst Ratings (4)

+514.89% upside

Buy

3 Buy

1 Hold

0 Sell

Current: 1.41

Low

5.00

Average

8.67

High

12.00

H.C. Wainwright

Buy

$8

2026-10-01

H.C. Wainwright

2026-10-01

Price Target

$8

Buy

Raymond James

Strong Buy

$10

2026-06-26

Raymond James

2026-06-26

Price Target

$10

Strong Buy

JonesResearch

Buy

$10

2026-06-26

JonesResearch

2026-06-26

Price Target

$10

Buy

Chardan

Buy

$3

2026-06-25

Chardan

2026-06-25

Price Target

$3

Buy

Oppenheimer

Outperform

$9

2026-03-12

Oppenheimer

2026-03-12

Price Target

$9

Outperform

See All Ratings

Valuation Metrics

The current forward P/E ratio for ProQR Therapeutics NV (PRQR) is 0.00, compared to its 5-year average forward P/E of -5.02.

Forward P/E

Overvalued

5Y Average P/E

-5.02

Current P/E

0.00

Overvalued

-2.23

Undervalued

-7.82

Forward EV/EBITDA

Undervalued

5Y Average EV/EBITDA

-1.65

Current EV/EBITDA

-5.68

Overvalued

0.89

Undervalued

-4.18

Forward P/S

Fair

5Y Average P/S

14.77

Current P/S

10.53

Overvalued

41.92

Undervalued

-12.39

Alphio AI Price Scenarios for PRQR

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PRQR

$2.08

Scenario price

B

Base

Base · 50%PRQR

$1.82

Scenario price

B

Bear

Bear · 25%PRQR

$1.58

Scenario price

Whales holding PRQR

A

Affinity Asset Advisors, LLC

+ HoldingPRQR

-21.37%

3M Return

PRQR FAQ — answered by Alphio AI

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ProQR Therapeutics is currently trading at $1.32, significantly below its 52-week high of $2.65, indicating potential upside. However, the stock has a low RSI of 39.15, suggesting it is nearing oversold territory, but it also reflects weak momentum. The company has a gross margin of 100%, which is excellent, but it has reported consistent net losses, with a net income loss of €13,383,000 in Q1 2026. The main risk is the company's ongoing financial losses and reliance on external financing, as evidenced by a recent direct offering that caused a 20% drop in share price. Given these factors, it may be prudent to hold rather than buy at this time, as the stock may need to stabilize before a clear buying opportunity arises.

4 analysts cover PRQR: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 8.67.